Lung Cancer Blood Flow: What Your Doctor Needs to Know
"New research unveils how different types of lung cancer—squamous cell carcinoma and adenocarcinoma—show unique blood flow patterns, potentially transforming treatment strategies."
Angiogenesis, the creation of new blood vessels, is vital for tumor growth. By studying these vascular patterns, doctors can better understand and characterize different tissues. CT perfusion (CTp) is a promising technology that provides high-resolution spatial and temporal data, which helps in computing perfusion parameters by analyzing time-concentration curves (TCCs). These curves are generated as a contrast agent reaches the tumor, offering insights into its blood supply.
One of the most valuable perfusion parameters for evaluating angiogenesis is blood flow (BF). BF has a strong correlation with microvessel density (MVD), a key tissue biomarker. Measuring BF involves tracking the initial passage of a contrast medium, allowing for quick examinations that minimize radiation exposure. Clinically, BF information obtained at diagnosis can help characterize lesions, particularly in patients who are not eligible for surgery but need non-surgical treatments. Higher baseline BF values in advanced lung cancer patients may also indicate a better response to specific therapies.
Differences in BF values between patients who respond to treatment and those who do not have spurred interest in characterizing tumors based on their hemodynamic properties, including their histological subtypes. Characterizing non-small cell lung cancer (NSCLC) perfusion can provide valuable insights into a tumor's status, especially regarding its hypoxia (oxygen deficiency). Adenocarcinoma (AC), for instance, typically has a lower degree of hypoxia compared to squamous cell carcinoma (SCC). By understanding these differences, treatments can be tailored to improve outcomes.
From Pulmonary Circulation to Modern Lung Cancer Care
Understanding pulmonary circulation has a long history, with William Harvey's 1628 theory of blood circulation serving as a starting point for some historical accounts. A 2021 review describes human pulmonary circulation as a field marked by mysteries, surprises, and continuing efforts to understand the lungs and their vessels. Lung cancer treatment also passed important milestones, including combination chemotherapy for small cell lung cancer and palliative chemotherapy for advanced non-small cell lung cancer. Later research examined the genomic and host factors involved in the progression of pre-invasive non-small cell lung cancer lesions.
Decoding Blood Flow in Lung Cancer: Adenocarcinoma vs. Squamous Cell Carcinoma
A recent study aimed to evaluate the distinct characteristics of lung tumors at diagnosis, focusing on potential differences in perfusion between adenocarcinoma (AC) and squamous cell carcinoma (SCC), the two most common NSCLC phenotypes. Previous research has presented conflicting results in AC and SCC perfusion characterization due to high measurement variability from clinical, physiological, and external factors (like patient movement and artifacts). To mitigate this variability, the study used an automatic method to detect and remove unreliable perfusion values.
- Study Design: The study involved 26 patients with primary NSCLC (19 AC and 7 SCC) who underwent CT perfusion at diagnosis.
- Data Collection: BF values were computed using the maximum-slope method, and unreliable values (e.g., those arising from artifacts or vessels) were automatically removed.
- Statistical Analysis: A one-tail Welch’s t-test was used to assess statistical significance, with a p-value < 0.05 indicating significance.
Why Blood-Flow Assessment and Treatment Remain Difficult
Lung cancer care remains complex because of drug resistance, disease recurrence, and treatment-related adverse effects. Cardiovascular effects from lung cancer treatments can require coordinated care involving oncologists, cardiologists, and other specialists. In one study of non-small cell lung cancer, researchers used 15O-water positron emission tomography to evaluate tumor blood flow before and after chemotherapy with bevacizumab, illustrating the effort needed to measure how anti-angiogenic treatment affects tumors.
Tumor Type and Treatment Response
A report on lung cancer blood flow states that blood-flow characteristics can differ among types of lung cancer and may affect the effectiveness of anti-angiogenic therapies. It presents these differences as potentially relevant to personalized treatment plans. The report specifically frames the comparison around adenocarcinoma and squamous cell carcinoma, the two most common non-small cell lung cancer phenotypes.
Future Implications for Lung Cancer Treatment
This research underscores the importance of understanding the unique blood flow characteristics of different lung cancer subtypes. By using CT perfusion to identify these patterns, doctors can make more informed decisions about treatment strategies, especially regarding antiangiogenic therapies for adenocarcinoma. Further studies are needed to explore these findings in larger patient cohorts and to investigate additional factors that may influence perfusion values. The ability to accurately profile tumors based on their perfusion characteristics holds great promise for personalized medicine in lung cancer treatment.
Expanding Detection and Treatment Frontiers
Over the past decade, lung cancer management has been reshaped by advances in early detection, treatment, and prevention. Prevention efforts now extend beyond tobacco control to non-tobacco risk factors, screening, and incidental nodule programs, although regional disparities remain. Current research includes immunotherapy and targeted therapies, along with early-detection approaches using blood, sputum, and artificial intelligence.
Evidence Beyond Clinical Trials
Non-small cell lung cancer remains a leading cause of global mortality, while conventional screening and diagnostic methods can lack sensitivity and specificity. Liquid biopsy research is being used to pursue precise, objective, and accessible diagnostic biomarkers for non-small cell lung cancer. Real-world data studies can help address evidence gaps by showing how cancer treatments perform in real-world settings. Such studies may also improve applicability beyond conventional clinical trials, which can be time-consuming, expensive, and difficult for patients to join.